Where Morphological and Molecular Classifications Meet: The Role of p53 Immunohistochemistry in the Prognosis of Low-Risk Endometrial Carcinoma (GLAMOUR Study). in Cancers / Cancers (Basel). 2024 Mar 7;16(6):1088. doi: 10.3390/cancers16061088.

2024
ASL Città di Torino
ASL Cuneo 1

Tipo pubblicazione

Journal Article

Autori/Collaboratori (36)Vedi tutti...

Migliaretti G
Department of Gynecology and Obstetrics, ASL Citta' di Torino, 10126 Torino, Italy.
Provenza C
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Borghese M
Department of Gynecology and Obstetrics, ASL Citta' di Torino, 10126 Torino, Italy.

et alii...

Abstract

No prospective study has validated molecular classification to guide adjuvant treatment in endometrial cancer (EC), and not even retrospective data are present for patients with morphological low-risk EC. We conducted a retrospective, multicenter, observational study including 370 patients with low-risk endometrioid EC to evaluate the incidence and prognostic role of p53 abnormal expression (p53abn) in this specific subgroup. Among 370 patients, 18 had abnormal expressions of p53 (4.9%). In 13 out of 370 patients (3.6%), recurrences were observed and two were p53abn. When adjusting for median follow-up time, the odds ratio (OR) for recurrence among those with p53abn versus p53 wild type (p53wt) was 5.23-CI 95% 0.98-27.95, p = 0.053. The most common site of recurrence was the vaginal cuff (46.2%). One recurrence occurred within the first year of follow-up, and the patient exhibited p53abn. Both 1-year and 2-year DFS rates were 94.4% and 100% in the p53abn and p53wt groups, respectively. One patient died from the disease and comprised p53wt. No difference in OS was registered between the two groups; the median OS was 21.9 months (16.4-30.1). Larger multicenter studies are needed to tailor the treatment of low-risk EC patients with p53abn. Performing molecular classification on all EC patients might be cost-effective, and despite the limits of our relatively small sample, p53abn patients seem to be at greater risk of recurrence, especially locally and after two years since diagnosis.

Accesso banca dati bibliografica

PMID : 38539423

DOI : 10.3390/cancers16061088

Keywords

target therapy; p53; endometrial cancer; molecular classification;